These include, e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, ergot derivatives, gepants, and ditans for the acute treatment for migraines and calcitonin-gene-related peptide (CGRP) monoclonal antibodies, onabotulinumtoxinA, calcium channel blockers (CCBs), beta-blockers, and anticonvulsants for prophylactic treatment for migraines. The gene discussed is CALCA; the disease is migraine disorder.